Pharma funds top charts with over 19% gains

GreyOak summary

Pharma and healthcare mutual funds delivered 19.15% year-to-date returns in 2026, outperforming other categories. Experts attribute this to US generics market improvements, CDMO opportunities, and domestic hospital growth, though they caution investors to assess valuations before chasing the rally.